Plain-English translation of NCT06620627 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at Natera are developing a new blood test called the Natera Screening Assay that may help detect colorectal cancer earlier than current methods. This study collects blood samples from people undergoing routine screening colonoscopies to help refine and validate this new test. By participating, you'd help researchers understand whether this blood test can accurately identify early signs of cancer.
Colorectal cancer is often easier to treat when caught early, but current screening methods aren't perfect. This study aims to develop a simple blood test that could catch cancer earlier and give people more treatment options.
You likely qualify if…
You likely don't qualify if…
You would give a blood sample at the study visit, and then have a colonoscopy performed within 120 days (as you were already planning). The researchers will keep your blood sample and use it to develop and test the new blood test—but they won't share the blood test results with you or your doctor during this study. Your participation helps validate whether this new screening tool works.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States
Sponsor
Natera, Inc.
Enrollment target
~5,000 participants
Started
January 2024
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Natera PROCEED-CRC Study team
Natera, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.